NCCN Guidelines® Insights - Thyroid Carcinoma, Version 2.2014
These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for Thyroid Carcinoma
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Thyroid Carcinoma
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician